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What’s the Matter, Mary Jane? How a Lack of
Prior Art Complicates the Patentability of
Marijuana
BY DUSTIN BOONE/ ON FEBRUARY 5, 2019

The marijuana industry is one that boasts a value of over $40 billion.[1] As public opinion continues to change
in favor of legalization and new research is performed,[2] America is swiftly becoming “the land of the red,
white, and green,” with an ever-increasing number of states legalizing marijuana for broad use and
consumption.[3] However, marijuana still remains illegal under federal law due to its treatment by the federal
government under the Controlled Substances Act (“CSA” or “the Act”). Congress passed the CSA in 1970 as
part of an ongoing effort to regulate controlled substances and decrease abuse of such substances in the United
States.[4]

The marijuana industry continues to grow, and as the “industry is emerging from the shadows,”[5] developers
are becoming more inclined to seek intellectual property protection for their creations and
innovations.[6] Developers are particularly interested in patent protection for many reasons, not the least of

which is that patents are “the strongest form of [intellectual property] protection” available.[7] Additionally,
developers seek patent protection because of the subject matter it can protect (including specific strains,
formulations, growing methods, and therapeutic uses).[8] Perhaps most importantly, the fact that there is
generally no requirement of legality for a subject matter to be patentable is appealing to marijuana growers and
developers. In other words, “[t]he status of cannabis as a Schedule I controlled substance is not relevant to
patentability.”[9] However, this does not mean that marijuana’s continued federal illegality does not give rise to
unique challenges in the patent realm.

One of the most prevalent of these challenges relates to the novelty requirement for patentability, which dictates
that the thing for which protection is being sought cannot have previously been disclosed to the public in any
manner.[10] Formal documentation that the innovation being claimed already exists in the world, known as
“prior art,” is used “during review of applicants’ patent applications and is often cited against applications to
reject them if the idea… has already been publicly known.”[11] Very little documentation exists related to
marijuana strains and formulations, or the progression of innovation within the industry because many breeders
and consumers of marijuana did so in secret for many years,[12] As a general matter, the importance of prior art
generally is paramount because, “[w]ithout that prior art library, the patent examiners are left with no choice but
to allow the patents to issue.”[13] Thus, with respect to marijuana, there exists the danger that “a wave of
patents” considered too broad in scope will be issued after only “a limited body of prior art” is examined,
leaving the system open for potential abuse.[14]

Without prior art, an individual could essentially obtain a patent for something that already exists within the
public domain.[15] More specifically, it is possible for someone to “claim a utility patent on a certain family of
cannabis strains, and convince an examiner it’s new because there’s no recorded precedent.”[16] The
implication of this problem is that if overly broad patents are enforced (enforcement of a marijuana patent has
not yet been done by a court, although the first marijuana-related patent infringement suit is pending[17]),
innovation in the industry could be stifled because, with no reservoir of prior art to use to challenge the validity
of the patent, developers could be forced to stop their work and pay damages for infringement.[18] This has a
particularly concerning potential outcome in the context of medical marijuana because “those who try to create
useful cannabis medicine” might become “curtailed by undue patents,” specifically “utility patents, which cover
entire genres of cannabis, [and could] prevent important medicines from reaching sick people.”[19]

The medical marijuana industry has begun to take on the challenge of addressing this issue in much the same
way the software industry in its infancy responded to difficulties in locating prior art.[20] One way the industry
is responding is through the ongoing maintenance of the Open Cannabis Project (“OCP”), an organization that
works to compile DNA sequences of marijuana strains into a public database.[21] Their mission “is to create
evidence of prior art, which helps to ensure that patents are not issued on plants that already exist.”[22] OCP’s
database is very useful because it serves as a “repository” of prior art, which can be referenced by the USPTO
when making decisions about the alleged patentability of marijuana strains or uses.[23] The database is thus
essential to prevent “existing cannabis strains from coming under the control of one commercial entity or
another.”[24]

While there is much more work to be done in addressing the tensions between marijuana’s federal illegality and
patent law, the work OCP is doing provides a nice start in ensuring that developers are protected from other
entities, particularly large corporations who want “to join the rush for patentable marijuana strains.”[25] Until

the day comes when an appropriate database of prior art exists for this industry, both the USPTO and federal
courts should use discretion in issuing and enforcing patents covering marijuana and marijuana-related goods
and technologies.
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